Hikma Pharma falls as it narrowly misses forecasts with 2018 results
Shares in Hikma Pharmaceuticals PLC (LON:HIK) dropped on Wednesday morning after the drugmaker narrowly missed forecasts with its 2018 results.
The FTSE 100 company, which makes everything from painkillers to antibiotics to thrombosis treatments, saw revenue rise 7% last year to US$2.07bn (2017: US$1.94bn), while operating profits jumped 19% to US$460mln (2017: US$386mln).
READ: Hikma secures anti-viral licensing deal
The top-line growth reflected “good demand for [its] in-market products and new product launches”, Hikma said, while profitability was driven by a “strong improvement” in margins in its generics business.
“The group has delivered a strong performance in 2018, with revenue and profitability significantly ahead of our expectations at the start of the year,” said chief executive Siggi Olafsson, who joined last year.
“Our injectables business continued to perform very well, demonstrating the diversification of our portfolio, the flexibility of our operations in responding to customer needs and our ability to bring important products to market.
He added: “The significant commercial and operational improvements we have made enabled our generics business to deliver strong growth and our Branded business continued to grow steadily.”
Shares down on slight miss, though
But shares fell almost 4% in early deals to 1,592p, as the numbers came in slightly below what the City had been expecting.
In a note to clients, analysts at Peel Hunt said: “2018 revenue US$2,07bn was 1% below Peel Hunt and company-gathered consensus.
“US$460m pre-ex operating profit was 2% below our forecasts and consensus, largely due to higher ‘other opex’ expense, which included impairment charges.”
Going forward, Hikma expects global injectables revenue to grow to between US$850-900mln in 2019, although margins are expected to fall slightly.
As for the generics business, revenue is likely to drop in the year ahead, although a pick-up in margins will partially offset that.
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/216368/hikma-pharma-falls-as-it-narrowly-misses-forecasts-with-2018-results-216368.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).